Interferon-α-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter

Journal of Psychopharmacology

Volumn 22, Issue 7, 2008, Pages 753-760

  Tsao, C W ^a   Lin, Y S ^b   Cheng, J T ^b   Lin, C F ^b   Wu, H T ^b   Wu, S R ^b   Tsai, W H ^b  

^a CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Depression; Interferon; Mitogen activated protein kinase; Serotonin transporter

Indexed keywords

ALPHA INTERFERON; FLUOXETINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SEROTONIN; SEROTONIN TRANSPORTER;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTONIN UPTAKE; WESTERN BLOTTING;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; HUMANS; INTERFERON-ALPHA; JURKAT CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 50249150354     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107082951     Document Type: Article

References (60)

1. Abe S., Hori T., Suzuki T., Baba A., Shiraishi H., Yamamoto T. (1999) Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 24: 359-363
2. Bethus I., Stinus L., Goodall G. (2003) Chronic interferon-alpha potentiates latent inhibition in rats. Behav Brain Res 144: 167-174
3. Cai W., Khaoustov VI, Xie Q., Pan T., Le W., Yoffe B. (2005) Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 42: 880-887
4. Capuron L., Dantzer R. (2003) Cytokines and depression: the need for a new paradigm. Brain Behav Immunol 17: S119 - S124
5. Capuron L., Ravaud A., Neveu PJ, Miller AH, Maes M., Dantzer R. (2002) Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7: 468-473
6. Capuron L., Neurauter G., Musselman DL, Lawson DH, Nemeroff CB, Fuchs D., Miller AH (2003 a) Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 54: 906-914
7. Capuron L., Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH (2003 b) Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 160: 1342-1345
8. Capuron L., Ravaud A., Miller AH, Dantzer R. (2004) Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immunol 18: 205-213
9. Castanon N., Bluthe RM, Dantzer R. (2001) Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1 beta in the rat. Psychopharmacology 154: 50-60
10. Connor TJ, Leonard BE (1998) Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 62: 583-606
11. Connor TJ, Harkin A., Kelly JP, Leonard BE (2000) Olfactory bulbectomy provokes a suppression of interleukin-1beta and tumour necrosis factor-alpha production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment. Neuroimmunomodulation 7: 27-35
12. Dang Y., Dale WE, Brown OR (2000) Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan2,3-dioxygenase of the kynurenine pathway. J Free Radic Biol Med 28: 615-624
13. David M., Petricoin E. III, Benjamin C., Pine R., Weber MJ, Larner AC (1995) Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. Science 269: 1721-1723
14. De La Garza R. II, Asnis GM (2003) The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res 977: 70-79
15. De La Garza R. II, Asnis GM, Pedrosa E., Stearns C., Migdal AL, Reinus JF, Paladuga R., Vemulapali S. (2005) Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog Neuropsychopharmacol Biol Psychiatry 29: 781-792
16. Einat H., Yuan P., Gould TD, Li J., Du J., Zhang L., Manji HK, Chen G. (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23: 7311-7316
17. Faraj BA, Olkowski ZL, Jackson RT (1994) Expression of a high-affinity serotonin transporter in human lymphocytes. Int J Immunopharmacol 16: 561-567
18. Fontana RJ (2000) Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 18: 107-116
19. Fumagalli F., Molteni R., Calabrese F., Frasca A., Racagni G., Riva MA (2005) Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain. J Neurochem 93: 1551-1560
20. Gladkevich A., Kauffman HF, Korf J. (2004) Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28: 559-576
21. Guillemin GJ, Kerr SJ, Pemberton LA, Smith DG, Smythe GA, Armati PJ, Brew BJ (2001) IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res 21: 1097-1101
22. Ha E., Jung KH, Choe BK, Bae JH, Shin DH, Yim SV, Baik HH (2006) Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells. Neurosci Lett 397: 185-189
23. Holmes A., Murphy DL, Crawley JN (2003) Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol Psychiatry 54: 953-959
24. Holsboer F. (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501
25. Kumai T., Tateishi T., Tanaka M., Watanabe M., Shimizu H., Kobayashi S. (2000) Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci 67: 663-669
26. Lesch KP, Bengel D., Heils A., Sabol SZ, Greenberg BD, Petri S., Benjamin J., Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531
27. Levenson JL, Fallon HJ (1993) Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 88: 760-761
28. Li Y., Sassano A., Majchrzak B., Deb DK, Levy DE, Gaestel M., Nebreda AR, Fish EN, Platanias LC (2004) Role of p38α Map kinase in Type I interferon signaling. J Biol Chem 279: 970-979
29. Loftis JM, Hauser P., Macey TA (2006 a) Can rodents be used to model interferon-α-induced depressive symptoms? Prog Neuropsychopharmacol Biol Psychiatry 30: 1364-1365
30. Lofits JM, Wall JM, Pagel RL, Hauser P. (2006 b) Administration of pegylated interferon-alpha-2a or 2b dose not induce sickness behavior in Lewis rat. Psychoneuroendorcrinology 31: 1289-1294
31. Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D., Burke S., Akil H., Lopez JF, Watson SJ (2004) Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 55: 225-233
32. Maes M., Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., Meltzer H. (2001) Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNα-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 6: 475-480
33. Makino M., Kitano Y., Komiyama C., Takasuna K. (2000) Human interferon-alpha increases immobility in the forced swimming test in rats. Psychopharmacology (Berl) 148: 106-110
34. Marazziti D., Rossi A., Giannaccini G., Baroni S., Lucacchini A., Cassano GB (1998) Presence and characterization of the serotonin transporter in human resting lymphocytes. Neuropsychopharmacology 19: 154-159
35. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y., Snyder AZ (2004) Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry 55: 217-224
36. Morikawa O., Sakai N., Obara H., Saito N. (1998) Effects of interferon-α, interferon-γ and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349: 317-324
37. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S., Goodkin RS, Greiner K., Nemeroff CB, Miller AH (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344: 961-966
38. Pace TW, Hu F., Miller AH (2007) Cytokine effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immunol 21: 9-19
39. Pariante CM, Miller AH (2001) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404
40. Platanias LC (2003) The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 98: 129-142
41. Pokrovskaja K., Panaretakis T., Grander D. (2005) Alternative signaling pathways regulating type I interferon-induced apoptosis. J Interferon Cytokine Res 25: 799-810
42. Purselle DC, Nemeroff CB (2003) Serotonin transporter: a potential substrate in the biology of suicide. Neuropsychopharmacology 28: 613-619
43. Raison CL, Demetrashvili M., Capuron L., Miller AH (2005) Neuropsychiatric adverse effects of interferon-α: recognition and management. CNS Drugs 19: 105-123
44. Raison CL, Capuron L., Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31
45. Ramamoorthy S., Bauman AL, Moore KR, Han H., Yang-Feng T., Chang AS, Ganapathy V., Blakely RD (1993) Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 90: 2542-2546
46. Reyes-Vazquez C., Prieto-Gomez B., Dafny N. (1994) Alpha-interferon suppresses food intake and neuronal activity of the lateral hypothalamus. Neuropharmacology 33: 1545-1552
47. Sakash JB, Byrne GI, Lichtman A., Libby P. (2002) Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-associated cells: implications for persistent Chlamydophila pneumoniae infection. Infect Immun 70: 3959-3961
48. Sammut S., Goodall G., Muscat R. (2001) Acute interferon-alpha administration modulates sucrose consumption in the rat. Psychoneuroendocrinology 26: 261-272
49. Samuvel DJ, Jayanthi LD, Bhat NR, Ramamoorthy S. (2005) A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J Neurosci 25: 29-41
50. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C., Meyer J., Gunn RN, Grasby PM, Cowen PJ (2000) Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174-180
51. Scheibel RS, Valentine AD, O'Brien S., Meyers CA (2004) Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 16: 185-191
52. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG (2000) Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 173: 359-361
53. Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51: 215-235
54. Tsao CW, Lin YS, Cheng JT, Chang WW, Chen CL, Wu SR, Fan CW, Lo HY (2006) Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol 63: 106-115
55. Van Gool AR, Fekkes D., Kruit WH, Mulder PG, Ten Hagen TL, Bannink M., Maes M., Eggermont AM (2003) Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res 119: 125-132
56. Wichers M., Maes M. (2002) The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 5: 375-388
57. Widmann C., Gibson S., Jarpe MB, Johnson GL (1999) Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143-180
58. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H., Bette M., Weihe E., Weidenfeld J. (2001) Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 24: 531-544
59. Zhu CB, Hewlett WA, Feoktistov I., Biaggioni I., Blakely RD (2004) Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation. Mol Pharmacol 65: 1462-1474
60. Zhu CB, Blakely RD, Hewlett WA (2006) The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31: 2121-2131